Viewing Study NCT05922904


Ignite Creation Date: 2025-12-24 @ 7:50 PM
Ignite Modification Date: 2026-01-05 @ 6:11 PM
Study NCT ID: NCT05922904
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-10
First Post: 2023-06-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module